Lexeo Q2 net loss $25.9M; initiates LX2006 pivotal trial, gains RMAT for LX2020

Lexeo Therapeutics, Inc.

Net loss $25.9M ($0.30/sh) vs $26.1M ($0.60/sh) YoY; R&D $19.0M vs $14.7M, G&A $9.0M vs $16.0M.
Cash, equivalents and investments $234.2M expected to fund operations into 2028.
First patient enrolled in SUNRISE-FA 2 pivotal trial for LX2006 in FA cardiomyopathy; topline data expected 2H 2027.
FDA granted RMAT designation for LX2020 in PKP2-ACM; 12-month high-dose data update expected Q4 2026.
LX2006 data published in JAMA Cardiology showing generally well tolerated with signs of efficacy in Phase I/II.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.